secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2026-06-26T22:18:31+00:00
Accession:  0001193125-26-286273
Event type: regulatory
Sentiment:  positive
Materiality: 0.95
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian Therapeutics receives FDA approval for Lumvoa (veligrotug-vvze) to treat thyroid eye disease
--------------------------------------------------------------------------------

- Lumvoa is the first FDA-approved treatment for TED with labeling covering both active and chronic disease.
- Approval supported by positive Phase 3 THRIVE and THRIVE-2 trials meeting primary and all secondary endpoints.
- Lumvoa showed statistically significant improvement in diplopia response and complete resolution in active and chronic TED.
- Viridian plans to launch Lumvoa immediately with a comprehensive patient support program (ViridianCares).
- Company will host a conference call on June 29, 2026, at 8:00 a.m. ET to discuss the approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/0001193125-26-286273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312526286273/d164211d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-286273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer